Erratum to "Features of Postpartum Hemorrhage-Associated Thrombotic Microangiopathy and Role of Short-Term Complement Inhibition" [<i>Kidney International Reports</i> Volume 9, Issue 4, April 2024, Pages 919-928].
對於「Features of Postpartum Hemorrhage-Associated Thrombotic Microangiopathy and Role of Short-Term Complement Inhibition」的更正 [<i>Kidney International Reports</i> 第9卷，第4期，2024年4月，頁919-928]。
Kidney Int Rep 2024-10-21
Corrigendum to "WCN24-1897 MONOCLONAL GAMMOPATHY OF RENAL SIGNIFICANCE AND MONOCLONAL IMMUNOGLOBULIN RELATED KIDNEY DAMAGE IN B-CELL MALIGNANCIES: THE REAL CLINICAL PRACTICE" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Page S624-S625].
對於「WCN24-1897 MONOCLONAL GAMMOPATHY OF RENAL SIGNIFICANCE AND MONOCLONAL IMMUNOGLOBULIN RELATED KIDNEY DAMAGE IN B-CELL MALIGNANCIES: THE REAL CLINICAL PRACTICE」的更正 [<i>Kidney International Reports</i> 第9卷，第4期，補充，2024年4月，頁S624-S625]。
Kidney Int Rep 2024-07-31
Corrigendum to "WCN24-1051 CLINICAL PROFILE, DIAGNOSIS, THERAPEUTIC INTERVENTION AND COMPLICATIONS IN RENAL BIOPSY IN CKD POPULATION - SINGLE CENTER 20 YEARS' EXPERIENCE" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Page S86].
對於「WCN24-1051 CLINICAL PROFILE, DIAGNOSIS, THERAPEUTIC INTERVENTION AND COMPLICATIONS IN RENAL BIOPSY IN CKD POPULATION - SINGLE CENTER 20 YEARS' EXPERIENCE」的更正 [<i>Kidney International Reports</i> 第9卷，第4期，補充，2024年4月，第S86頁]。
Kidney Int Rep 2024-07-31
Corrigendum to "WCN24-1267 EMPAGLIFLOZIN IMPROVES VITALITY AND PROTECT FROM ADVANCED GLYCATION END PRODUCTS IN ENDOTHELIAL CELLS" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Page S637].
對於「WCN24-1267 EMPAGLIFLOZIN 改善活力並保護內皮細胞免受高級糖化終產物的影響」的更正 [<i>Kidney International Reports</i> 第9卷，第4期，補充，2024年4月，第S637頁]。
Kidney Int Rep 2024-07-31
Corrigendum to "Analysis and Management of Rituximab Resistance in PLA2R1-Associated Membranous Nephropathy" [<i>Kidney International Reports</i> Volume 6, Issue 4, April 2021, Pages 1183-1188].
對於「Analysis and Management of Rituximab Resistance in PLA2R1-Associated Membranous Nephropathy」的更正 [<i>Kidney International Reports</i> 第6卷，第4期，2021年4月，頁1183-1188]。
Kidney Int Rep 2024-07-31
Corrigendum to "WCN24-1066 BRIDGING THE GAP: INTEGRATING THE MULTIDISCIPLINARY EQUIPMENT ON HEMODIALYSIS VASCULAR ACCESS FROM LATIN AMERICA AND PERÚ" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Page S379-S380].
更正「WCN24-1066 橋接差距：整合拉丁美洲和秘魯的多學科血液透析血管通路設備」[<i>Kidney International Reports</i> 第9卷，第4期，補充，2024年4月，頁S379-S380]。
Kidney Int Rep 2024-08-19
看起來你提到的是一篇有特定 DOI 的文章的更正。如果你需要幫助理解這個更正、總結文章內容，或是有其他相關的問題，請提供更多細節！
PubMedDOI
Corrigendum to "Atypical Clinical Presentation of Autosomal Recessive Polycystic Kidney Mimicking Medullary Sponge Kidney Disease" [<i>Kidney International Reports</i> Volume 7, Issue 4, April 2022, Pages 916-919].
對於「Atypical Clinical Presentation of Autosomal Recessive Polycystic Kidney Mimicking Medullary Sponge Kidney Disease」的更正 [<i>Kidney International Reports</i> 第7卷，第4期，2022年4月，頁916-919]。
Kidney Int Rep 2024-08-19
Corrigendum to "WCN24-658 Comparative Analysis of Zwitterionic Materials and Polyvinyl Pyrrolidone for Enhancing Dialysis Membrane Hemocompatibility and Psychological Symptoms in Patients" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Pages S362-S363].
對於「WCN24-658 比較分析 Zwitterionic 材料和聚乙烯吡咯烷酮以增強透析膜的血液相容性及患者的心理症狀」的更正 [<i>Kidney International Reports</i> 第9卷，第4期，補充，2024年4月，頁S362-S363]。
Kidney Int Rep 2024-08-19
看起來你提到的是一篇有特定 DOI 的文章的更正。如果你需要幫助理解這個更正、總結文章內容，或是有其他相關的問題，請提供更多細節！
PubMedDOI
Corrigendum to "WCN24-465 RISK OF MORTALITY IN PATIENTS RECEIVING HIGH-VOLUME ONLINE HEMODIAFILTRATION (OL-HDF) VERSUS HIGH-FLOW HEMODIALYSIS (HD) THERAPY IN 14 FRESENIUS MEDICAL CARE ECUADOR (FMC) CLINICS" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Page S359].
對於「WCN24-465 高容量線上血液透析 (OL-HDF) 與高流量血液透析 (HD) 治療在 14 家 Fresenius Medical Care Ecuador (FMC) 診所中患者死亡風險的比較」的更正 [<i>Kidney International Reports</i> 第 9 卷，第 4 期，補充，2024 年 4 月，第 S359 頁]。
Kidney Int Rep 2024-08-19
看起來你提到的是一篇有特定 DOI 的文章的更正。如果你需要幫助理解這個更正、總結文章內容，或是其他相關資訊，請提供更多細節！
PubMedDOI
Corrigendum to "WCN24-1709 NON-CADAVERIC HOMOLOGOUS VEIN AS VASCULAR ACCESS IN A PATIENT WITH EXHAUSTED NATIVE VEINS ON HEMODIALYSIS" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Pages S398-S399].
對於「WCN24-1709 非屍體同源靜脈作為一名在透析中原生靜脈耗竭患者的血管通路」的更正 [<i>Kidney International Reports</i> 第9卷，第4期，補充，2024年4月，頁S398-S399]。
Kidney Int Rep 2024-08-19
Corrigendum to "WCN24-2499 CAVEOLIN-1 AND CAVEOLIN-2 AS POTENTIAL URINARY EARLY BIOMARKERS OF RENAL INJURY IN ACUTE CHOLESTASIS IN RATS" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Page S541].
對於「WCN24-2499 CAVEOLIN-1 和 CAVEOLIN-2 作為急性膽汁淤積大鼠腎損傷的潛在尿液早期生物標記」的更正 [<i>Kidney International Reports</i> 第9卷，第4期，補充，2024年4月，第S541頁]。
Kidney Int Rep 2024-08-19